Objective: Recombinant activated factor VII (rFVIIa) is being increasingly used in cardiac surgical patients with refractory hemorrhage. In this study, the authors assessed the ability of thromboelastography (TEG) in guiding rFVIIa therapy in this setting.
XCESSIVE BLEEDING IS A common complication of on-pump cardiac surgery that is independently linked to serious postoperative complications. 1 In a subset of patients, standard hemostatic interventions, which include the use of antifibrinolytic drugs, surgical re-exploration, and blood component therapy, fail to stop or reduce the blood loss in a timely manner. Physicians are increasingly treating these cases of refractory hemorrhage with recombinant activated factor VII (rFVIIa), [2] [3] [4] which constitutes an off-label use of a hemostatic drug that is currently approved primarily for hemophiliac patients with inhibitors.
Although the overall risk-benefit profile of the off-label use of rFVIIa in this setting has not yet been elucidated fully, there is increasing evidence that its benefits outweigh its (mainly thrombotic) risks in selected cases. [4] [5] [6] A substantial proportion of patients with refractory hemorrhage, however, do not respond to rFVIIa. 7 Given that rFVIIa therapy is not risk free, the ability to predict and monitor response to rFVIIa would confer important benefits. Previous studies have identified several patient-related factors and laboratory tests that are associated with a lack of response. Examples of the former include acidosis and hypothermia, 8, 9 and examples of the latter include thrombocytopenia (Ͻ80 ϫ 10 6 ) and elevated prothrombin time (PT Ͼ2.0). 7, [10] [11] [12] The predictive value of these factors for lack of response, however, is relatively modest. Similarly, there are no reliable means of monitoring the effects of rFVIIa.
It has been proposed that thromboelastography (TEG), which, unlike standard tests of coagulation that are performed on platelet-poor plasma, is performed on whole blood and provides information on the entire clotting process, including initiation and speed of clot formation, clot strength, and fibrinolysis, may be more useful for predicting and monitoring the effects of rFVIIa. 13, 14 In bleeding hemophiliac patients with inhibitors, TEG was found to be useful for monitoring the effects of rFVIIa. [14] [15] [16] There are also 2 recent case reports describing the ability of TEG to guide rFVIIa therapy in hemophiliacs undergoing surgery. 17, 18 Authors of these studies noticed that rFVIIa increased the clot strength in a dosedependent manner as measured by TEG. However, whether TEG is similarly useful in bleeding cardiac surgical patients without hemophilia is not known.
Consequently, the authors performed this retrospective study in nonhemophiliac patients who received rFVIIa for refractory hemorrhage after cardiac surgery to determine if TEG could identify coagulation defects that are undetected by standard coagulation tests or be used to guide rFVIIa therapy.
METHODS
After approval of the institutional research ethics board, detailed perioperative data, including patient demographics, surgical information, timing and number of blood product transfusions, perioperative medications including drugs affecting coagulation, laboratory tests, and postoperative outcomes, were retrospectively obtained on consecutive patients who received rFVIIa (Novo Nordisk, Bagsaerd, Denmark) for refractory hemorrhage after cardiac surgery from 2005 to 2007 and in whom coagulation tests, including TEG, were performed within 30 minutes before and after rFVIIa therapy. Data were obtained from prospectively collected clinical databases that include detailed perioperative information on all cardiac surgery patients.
As has been described in detail elsewhere, 4 institutional guidelines required that patients meet all of the following criteria before rFVIIa was to be considered: (1) at least 4 units of red blood cells were transfused or blood loss exceeded 2,000 mL or was brisk enough to preclude sternal closure in the operating room, (2) a surgical source of bleeding was excluded by at least 2 hours of surgical re-exploration after the termination of CPB and reversal of heparin or by returning to the operating room for re-exploration, (3) antifibrinolytics were given, (4) patients had received at least 4 units of fresh frozen plasma and 5 units of platelets, (5) standard coagulation parameters were within 50% of the limits of normal, and (6) hematocrit concentration was at least 24%. The recommended dosage of rFVIIa was 35 g/kg, rounded to the nearest ampoule size (1.2, 2.4, or 4.8 mg), repeated as necessary. NOTE. All variables are presented as n (%) or median (range). Liver dysfunction, defined as aspartate aminotransferase Ͼ40 IU/L or alanine aminotransferase Ͼ42 IU/L.
Abbreviations: rFVIIa, recombinant factor VIIa; renal dysfunction, calculated creatinine clearance Ͻ60 mL/min; ascending aorta/arch, surgery on ascending aorta or aortic arch; congenital, surgery for complex adult cardiac congenital disease; single valve/ACB, isolated coronary artery bypass grafting or single valve surgery; other, other cardiac surgical procedure; received aprotinin, all others received tranexamic acid. Abbreviations: rFVIIa, recombinant factor VIIa; RBC, units of packed red blood cells transfused; FFP, units of fresh frozen plasma transfused; platelets, units of platelets transfused; chest tube loss, chest tubes blood loss in the 6 hours before administration of rFVIIa (before rFVIIa if chest tubes in place and in the 12 hours after rFVIIa administration) (12 hours). Coagulation tests performed on patients before and after rFVIIa as part of routine care consisted of international normalized ratio (INR) of the PT, partial thromboplastin time, fibrinogen level, hemoglobin concentration, platelet count, and TEG. TEG analyses (Table 1) were performed using the TEG 5000 analyzer (Haemoscope, Niles, IL), according to the manufacturer's instructions. As has been shown previously, citrated samples used for TEG purposes are not stable for the first 30 minutes of storage because of incomplete thrombin inhibition. 19, 20 Therefore, blood samples were collected and stored in 4.5-mL, 3.2% sodium citrate, blue top Vacutainers (Becton Dickinson, Sandy, UT) for approximately 30 minutes before they were analyzed to ensure reliability of the results.
TEG analyses were performed without activation (native), with kaolin activation, and with tissue factor (TF) activation in heparinase sampling cups. Samples were recalcified with calcium chloride (20 L added to the sampling cup). For the native analyses, 340 L of citrated blood was added to the sampling cup and gently mixed with the calcium chloride using a micropipette. For the TF-activated analyses, 10 L of diluted TF (Dade Behring, Marburg, Germany) was first added to the sampling cup and mixed with the calcium chloride 
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followed by 330 L of citrated blood. TF dilution was as follows: 10 mL of distillated water were added to the TF powder and 10 L of the resulting solution were diluted again with 10 mL of distillated water. For kaolin-activated analyses, 1 mL of blood was first transferred into a standard kaolin cup supplied by the manufacturer. The kaolin-activated, citrated blood (340 L) was then added to the sampling cup and mixed with the calcium chloride. Detailed perioperative variables, including patient demographics, comorbidities, surgical information, laboratory data, timing and amount of rFVIIa therapy and blood transfusions, and postoperative events, were retrospectively collected on all patients. The primary outcome of interest was response to rFVIIa, which was determined by a qualitative review of patients' records. Two investigators (M.M. and M.W.), blinded to the TEG data, independently reviewed all relevant records, including before and after rFVIIa therapy recorded blood loss (chest tube loses), blood product transfusion, and surgical procedures. Based on the totality of the data, they classified patients as responders or nonresponders. Generally, patients were classified as responders if they did not require chest reopening after rFVIIa therapy and had markedly less blood loss and received substantially fewer blood products after rFVIIa therapy than before rFVIIa therapy. In cases of disagreement, a third blinded investigator (K.K.) was to independently review the records and make the final determination. Descriptive statistics were used to describe measured variables. Standard statistical tests (Fisher exact test for categoric variables and Wilcoxon-Mann-Whitney test for continuous variables) were used to compare perioperative variables between responders and nonresponders. To investigate the ability of TEG to monitor the effects of rFVIIa, pre-and post-rFVIIa TEG values were compared by using the Wilcoxon signed rank test for each combination of activation method (native, kaolin, and TF) and parameter (r time, k time, ␣ angle, and maximum amplitude). Because these tests are correlated, the Bonferonni correction for multiple comparisons was not used. Rather, a conservative p of less than 0.01 was selected as the threshold for significance.
To investigate the ability of TEG to predict the response to rFVIIa, the relationships between the number of abnormalities in TEG measures before rFVIIa therapy and response to rFVIIa, as determined by the blinded investigators, were measured. For this analysis, patients were categorized as having 1, 2, or 3 TEG abnormalities before rFVIIa therapy, based on the measured r time, k time, and maximum amplitude. Alpha angle, another commonly used TEG parameter, was not used in this analysis because it essentially measures the same aspect of coagulation as k time. The relationship between the number of abnormalities and the response to rFVIIa was then determined with the Fisher exact test. For comparison, a similar analysis was performed by using the number of abnormalities in standard coagulation tests (INR Ͼ1.5, partial thromboplastin time Ͼ60 seconds, platelet count Ͻ80, and hemoglobin Ͻ8 g/dL) before rFVIIa therapy.
RESULTS
During the study period, 53 patients received rVIIa for refractory hemorrhage after cardiac surgery. Complete pre-and post-rFVIIa therapy coagulation data were available for 38 (72%) patients, and all of these patients were included in the study. In determining response to rFVIIa, the agreement rate between the 2 blinded reviewers was 100%; thus, adjudication by the third reviewer was not necessary. Twenty-eight patients (74 %) were classified as responders and 10 (26 %) as nonresponders. The primary source of blood loss was not surgical in any of the patients. Among the responders, 24 (86%) received 1 dose of rFVIIa (median, 35 g/kg; range, 25-66 g/kg), whereas 4 received a second dose (median, 34 g/kg; range, 28-41 g/kg). Among the nonresponders, only 2 received 1 dose (median, 43 g/kg; range, 34-49 g/kg), 7 received 2 doses (median, 50 g/kg; range, 23-71 &u;g/kg), and 1 patient received 3 doses of rFVIIa. Patient-and surgery-related variables are presented in Table 2 , and transfusion-related data are presented in Table 3 . Responders received substantially fewer blood products and had less blood loss than nonresponders.
Standard coagulation test results before and after rFVIIa therapy are presented in Table 4 . The tests suggest that nonresponders were more coagulopathic than responders both before and after rFVIIa therapy. The most pronounced change related to rFVIIa therapy was a reduction of the INR.
The results of the TEG parameters before and after rFVIIa therapy in responders and nonresponders are presented in Figures 1A and B, respectively. rFVIIa therapy was not associated with any significant change in any of the TEG parameters; with the exception of a reduction in the r time in TF-activated samples in nonresponders.
The relationships between the number of abnormal TEG values in kaolin-activated samples and response to rFVIIa are presented in Table 5 (the relationships between native and TF-activated samples were not as robust and, consequently, are not presented). The most predictive cutoff was 2 TEG value abnormalities; patients with fewer than 2 abnormalities had a 33-fold greater odd of responding to rFVIIa than those with 2 or 3 abnormalities. This compares favorably with the most predictive cutoff for standard laboratory tests. Figure 2 shows the differences in pre-therapy TEG values between responders and nonresponders.
DISCUSSION
This retrospective observational study of 38 patients without hemophilia who received rFVIIa for refractory hemorrhage after cardiac surgery had 2 important findings. First, it was found that rFVIIa therapy was not associated with clinically useful changes in TEG measures. In fact, in most of the studied patients, TEG parameters were within normal ranges before rFVIIa administration. Thus, TEG seems to have limited utility for identifying and monitoring coagulation defects in this setting. This finding is in conflict with data obtained on bleeding hemophiliac patients in whom abnormal baseline TEG values have been shown to be normalized with rFVIIa therapy in a dose-dependent manner. [14] [15] [16] [17] One possible explanation for these divergent findings is that the hemostatic defect in bleeding hemophiliac patients is different and much more specific than the defect in nonhemophiliac patients with refractory bleeding after cardiac surgery. 18,21 This is not surprising considering that cardiac surgery with cardiopulmonary bypass has a multifactorial impact on coagulation. 22 As in previous studies, 2, 3, 13 this study also found a consistent reduction of INR after rFVIIa therapy, which can be explained by the strong affinity of thromboplastin (used to measure PT) with activated factor VII, and it does not indicate a response to rFVIIa therapy.
Second, the authors found that patients with abnormal baseline TEG values were less likely to respond to rFVIIa than those with normal baseline TEG values. This is consistent with the emerging understanding that for rFVIIa to work in patients with refractory blood loss, an adequate number of clotting substrates need to be present. 4, 7, 10, 17 Moreover, abnormal TEG parameters were found to have a better predictive value for a lack of response to rFVIIa than abnormalities in standard tests 
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WĄ SOWICZ ET AL of coagulation. The clinical relevance of this finding needs to be assessed in larger trials. The present study had several limitations. First, the study had a small sample size, and, as such, it may have been underpowered to detect important changes in TEG values related to rFVIIa therapy. Second, this was not a prospective trial. Thus, patient management was not standardized. This means that the timing of laboratory tests related to rFVIIa therapy was not consistent and patients did receive blood products between the pre-and postlaboratory measures. Moreover, determination of response to rFVIIa had to be made retrospectively from patients' records. Although the 100% accuracy between the 2 blinded clinicians is encouraging, the possibility that some patients were misclassified cannot be excluded. Third, about one third of patients received aprotinin, which may have unduly influenced TEG measures. Aprotinin has been shown to prolong r times and reduce maximum amplitude measures. 22, 23 Fourth, because of institutional guidelines, the doses of rFVIIa 
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were lower than some recommendations and were somewhat standardized. For example, Ranuci et al 24 suggested that to achieve significant benefit patients should receive at least 50 g/kg. Others, however, have recommended lower doses. 5, 25 Nevertheless, because of the standardization of dosage, a dose-effect analysis could not be performed in this study. It is possible that the effects on coagulation parameters are dose-dependent.
In conclusion, it was found that although TEG had little ability in identifying and monitoring coagulation defects (changes) in nonhemophiliac cardiac surgical patients who required rFVIIa because of refractory hemorrhage, it did have some predictive value for identifying who would respond to rFVIIa therapy. Specifically, it was found that patients with 2 or more abnormalities in kaolin-activated TEG measures were less likely to respond to rFVIIa than those with fewer than 2 abnormalities. Given the outlined limitations of the study, however, these findings should be interpreted with caution. Whether TEG can be used as a screening tool before rFVIIa therapy needs to be investigated by larger prospective trials.
